scholarly journals The Role of Neutrophilic Inflammation, Angiotropism, and Pericytic Mimicry in Melanoma Progression and Metastasis

2016 ◽  
Vol 136 (2) ◽  
pp. 372-377 ◽  
Author(s):  
Jennifer Landsberg ◽  
Thomas Tüting ◽  
Raymond L. Barnhill ◽  
Claire Lugassy
BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Satu Salmi ◽  
Anton Lin ◽  
Benjamin Hirschovits-Gerz ◽  
Mari Valkonen ◽  
Niina Aaltonen ◽  
...  

Abstract Background FoxP3+ Regulatory T cells (Tregs) and indoleamine-2,3-dioxygenase (IDO) participate in the formation of an immunosuppressive tumor microenvironment (TME) in malignant cutaneous melanoma (CM). Recent studies have reported that IDO expression correlates with poor prognosis and greater Breslow’s depth, but results concerning the role of FoxP3+ Tregs in CM have been controversial. Furthermore, the correlation between IDO and Tregs has not been substantially studied in CM, although IDO is known to be an important regulator of Tregs activity. Methods We investigated the associations of FoxP3+ Tregs, IDO+ tumor cells and IDO+ stromal immune cells with tumor stage, prognostic factors and survival in CM. FoxP3 and IDO were immunohistochemically stained from 29 benign and 29 dysplastic nevi, 18 in situ -melanomas, 48 superficial and 62 deep melanomas and 67 lymph node metastases (LNMs) of CM. The number of FoxP3+ Tregs and IDO+ stromal immune cells, and the coverage and intensity of IDO+ tumor cells were analysed. Results The number of FoxP3+ Tregs and IDO+ stromal immune cells were significantly higher in malignant melanomas compared with benign lesions. The increased expression of IDO in melanoma cells was associated with poor prognostic factors, such as recurrence, nodular growth pattern and increased mitotic count. Furthermore, the expression of IDO in melanoma cells was associated with reduced recurrence˗free survival. We further showed that there was a positive correlation between IDO+ tumor cells and FoxP3+ Tregs. Conclusions These results indicate that IDO is strongly involved in melanoma progression. FoxP3+ Tregs also seems to contribute to the immunosuppressive TME in CM, but their significance in melanoma progression remains unclear. The positive association of FoxP3+ Tregs with IDO+ melanoma cells, but not with IDO+ stromal immune cells, indicates a complex interaction between IDO and Tregs in CM, which demands further studies.


2017 ◽  
Vol 137 (10) ◽  
pp. S293
Author(s):  
F. Ohno ◽  
T. Nakahara ◽  
M. Nakahara ◽  
S. Nunomura ◽  
K. Izuhara ◽  
...  

2007 ◽  
Vol 55 (1) ◽  
pp. S158
Author(s):  
A. M. DeLuca ◽  
B. Ryu ◽  
R. Alani

2006 ◽  
Vol 42 (8) ◽  
pp. 1181-1187 ◽  
Author(s):  
Oriana Simonetti ◽  
Gaia Goteri ◽  
Guendalina Lucarini ◽  
Alessandra Filosa ◽  
Tiziana Pieramici ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2284
Author(s):  
Serena Stamatakos ◽  
Giovanni Luca Beretta ◽  
Elisabetta Vergani ◽  
Matteo Dugo ◽  
Cristina Corno ◽  
...  

Metabolic changes promoting cell survival are involved in metastatic melanoma progression and in the development of drug resistance. In BRAF-inhibitor resistant melanoma cells, we explored the role of FASN, an enzyme involved in lipogenesis overexpressed in metastatic melanoma. Resistant melanoma cells displaying enhanced migratory and pro-invasive abilities increased sensitivity to the BRAF inhibitor PLX4032 upon the molecular targeting of FASN and upon treatment with the FASN inhibitor orlistat. This behavior was associated with a marked apoptosis and caspase 3/7 activation observed for the drug combination. The expression of FASN was found to be inversely associated with drug resistance in BRAF-mutant cell lines, both in a set of six resistant/sensitive matched lines and in the Cancer Cell Line Encyclopedia. A favorable drug interaction in resistant cells was also observed with U18666 A inhibiting DHCR24, which increased upon FASN targeting. The simultaneous combination of the two inhibitors showed a synergistic interaction with PLX4032 in resistant cells. In conclusion, FASN plays a role in BRAF-mutated melanoma progression, thereby creating novel therapeutic opportunities for the treatment of melanoma.


2007 ◽  
Vol 2 (2) ◽  
pp. 191-201
Author(s):  
Susan E Zabierowski ◽  
Meenhard Herlyn

2009 ◽  
Vol 10 (5) ◽  
pp. 455-464 ◽  
Author(s):  
Jun Li ◽  
Yemin Wang ◽  
Ronald Wong ◽  
Gang Li

Inflammation ◽  
2019 ◽  
Vol 42 (5) ◽  
pp. 1886-1900 ◽  
Author(s):  
M. C. Della Vedova ◽  
F. M. Soler Garcia ◽  
M. D. Muñoz ◽  
M. W. Fornes ◽  
Sandra E. Gomez Mejiba ◽  
...  

Author(s):  
Rajasekharan Somasundaram ◽  
Gao Zhang ◽  
Stephan N. Wagner ◽  
Mizuho Fukunaga-Kalabis ◽  
Meenhard Herlyn

Sign in / Sign up

Export Citation Format

Share Document